AI English summary of an SEC filing — figures as filed
ResMed RMDThe company said net revenue for the 3 months ended March 31, 2024 was $1,197.0 million, up $80.1 million or 7% from $1,116.9 million a year earlier (up 7% on a constant currency basis). It cited increased demand and unit sales as the factors behind the growth in Sleep and Respiratory Care revenue.
Key points
AI summaryThe company said net revenue for the 3 months ended March 31, 2024 was $1,197.0 million, up $80.1 million or 7% from $1,116.9 million a year earlier (up 7% on a constant currency basis). It cited increased demand and unit sales as the factors behind the growth in Sleep and Respiratory Care revenue.
ResMed said gross profit for the 3 months rose 12% to $692.8 million from $617.8 million a year earlier, and gross margin was 57.9% compared with 55.3% a year earlier. It cited reduced freight costs and manufacturing cost improvements as the factors behind the higher margin.
The company said net income for the 3 months was $300.5 million, up 29% from $232.5 million a year earlier, and diluted earnings per share were $2.04 compared with $1.58 a year earlier.
The company said net cash provided by operating activities for the 9 months ended March 31, 2024 was $961.1 million, compared with $455.9 million a year earlier. It cited a decrease in cash outflows from inventory purchases as a factor behind the increase.
Key figures
Quarter ended March 31, 2024
- Revenue
- $1.2B
- Operating income
- $375M
- Net income
- $300M
- EPS
- $2.04
- Gross profit
- $693M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Quarterly net revenue $1,197.0 million
The company said net revenue for the 3 months ended March 31, 2024 was $1,197.0 million, up $80.1 million or 7% from $1,116.9 million a year earlier (up 7% on a constant currency basis). It cited increased demand and unit sales as the factors behind the growth in Sleep and Respiratory Care revenue.
Source · Based on the MD&A text of the filing
Quarterly gross margin 57.9%
ResMed said gross profit for the 3 months rose 12% to $692.8 million from $617.8 million a year earlier, and gross margin was 57.9% compared with 55.3% a year earlier. It cited reduced freight costs and manufacturing cost improvements as the factors behind the higher margin.
Source · Based on the MD&A text of the filing
Quarterly net income $300.5 million
The company said net income for the 3 months was $300.5 million, up 29% from $232.5 million a year earlier, and diluted earnings per share were $2.04 compared with $1.58 a year earlier.
Source · Based on the MD&A text of the filing
Operating cash flow for 9 months $961.1 million
The company said net cash provided by operating activities for the 9 months ended March 31, 2024 was $961.1 million, compared with $455.9 million a year earlier. It cited a decrease in cash outflows from inventory purchases as a factor behind the increase.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…